Evidence map›Paper›PMID 35417093›Full record

ReviewEuropean journal of heart failure2022

Practical outpatient management of worsening chronic heart failure.

Nicolas Girerd, Nathan Mewton, Jean-Michel Tartière, Damien Guijarro, Patrick Jourdain, Thibaud Damy, Nicolas Lamblin, Antoni Bayes-Génis, Pierpaolo Pellicori, James L Januzzi and 3 more

Open access · bronzeAbstract readReview
In one paragraph

Review in European journal of heart failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
8.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 54 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Observational
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 9 institutions in 4 countries.

Nicolas GirerdCentre d'Investigation Clinique- Plurithématique Inserm CIC-P 1433, Inserm U1116, CHRU Nancy Brabois, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Université de Lorraine, Nancy, France.ORCID 0000-0002-3278-2057
Nathan MewtonHôpital Cardiovasculaire Louis Pradel Hospices Civils de Lyon Heart Failure Department Clinical Investigation Center Inserm 1407 CarMeN Inserm 1060, University Claude Bernard Lyon, Bron, France.
Jean-Michel TartièreCHITS, Department of Cardiology, Hôpital Sainte-Musse, Toulon, France.
Damien GuijarroCHU Nantes, CNRS, INSERM, l'institut Du Thorax, Université de Nantes, Nantes, France.
Patrick JourdainCovidom Regional Telemedicine Platform, Assistance Publique-Hôpitaux de Paris, Paris, France.
Thibaud DamyRéseau Cardiogen, Department of Cardiology, Centre Français de Référence de l'Amylose Cardiaque (CRAC), CHU d'Henri-Mondor, Créteil, France.
Nicolas LamblinDepartment of Cardiology, CHU de Lille, Université de Lille, Lille, France.
Antoni Bayes-GénisCIBERCV, Servicio de Cardiología, Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Barcelona, Spain.
Pierpaolo PellicoriRobertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK.
James L JanuzziCardiology Division, Massachusetts General Hospital, Baim Institute for Clinical Research, Harvard Medical School, Boston, MA, USA.
Patrick RossignolCentre d'Investigation Clinique- Plurithématique Inserm CIC-P 1433, Inserm U1116, CHRU Nancy Brabois, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Université de Lorraine, Nancy, France.
François RoubillePhyMedExp, Université de Montpellier, INSERM, CNRS, Cardiology Department, CHU de Montpellier, France.
a panel of multidisciplinary experts and the Heart Failure Working Group of the French Society of Cardiology
Centre National de la Recherche Scientifique · FRInserm · FRAssistance Publique – Hôpitaux de Paris · FRHarvard University · USHôpital d'Instruction des Armées Sainte-Anne · FRUniversitat Autònoma de Barcelona · ESUniversité Claude Bernard Lyon 1 · FRUniversité de Lille · FRUniversity of Glasgow · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Management of worsening heart failure (WHF) has traditionally been hospital-based, but with the rising burden of heart failure (HF), the pressure on healthcare systems exerted by this disease necessitates a different strategy than long (and costly) hospital stays. A strategy for outpatient intravenous (IV) diuretic treatment of WHF has been developed in certain American centres in the past 10 years, whereas European centres have been mostly favouring 'classic' in-hospital management of WHF. Embracing novel, outpatient approaches for treating WHF could substantially reduce the burden on healthcare systems while improving patient's satisfaction and quality of life. The present article is intended to provide essential knowledge and practical guidelines aimed at helping clinicians implement these new ambulatory approaches using day hospital and/or at-home hospitalization. The topics addressed by our group of HF experts include the pathophysiological background of diuretic therapy, the most suitable profile of WHF that may be managed in an ambulatory setting, the pharmacological protocols that can be used, as well as a detailed description of healthcare structures that can be proposed to deliver these ambulatory care interventions. The practical aspects of day hospital and hospital-at-home IV diuretic administration are specifically emphasized. The algorithm provided along with the practical IV diuretic protocols should assist HF clinicians in implementing this new approach in their local clinical setting.

Indexed as

Heart FailureChronic DiseaseDiureticsHospitalizationHumansOutpatientsQuality of LifeDiureticsAmbulatory managementCardiac congestionCardiovascular diseasesDiureticsHeart failure

Identifiers

PMID35417093
PMCPMC9325366
OpenAlexW4223573115

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.